BEAM
Structural scoring is not meaningful for this business
Structural scoring uses gross margin, free cash flow and Altman Z — measures built for operating companies. For banks, insurers and asset managers they produce artifacts, because the cash-flow statement is dominated by lending and deposit flows rather than operations. Treat the structural and composite figures below as not comparable with other sectors, in either direction.
- Reported free cash flow is far outside the range an operating business can show, indicating balance-sheet rather than operating flows
Daily closes · 1Y (252 sessions) · +79.9% · range 16.31–37.92
The Businesswhat the company reports
Business & cash flow
| FCF / assets | -24.3% |
|---|---|
| OCF / assets | -23.3% |
| FCF / revenue | -247.0% |
| Gross margin | -161.9% |
| ROIC | -27.7% |
| Forward P/E | -6.2 |
FCF/assets and OCF/assets are the cash-flow measures Brown Bear's own testing found to survive; FCF/revenue is shown alongside for context. Assets are from the latest annual filing (FY2025).
Price vs Earnings growth
Trailing EPS is negative (-0.69) and forward EPS is not positive, so a growth percentage does not exist
Confidence 35.0/100
Drivers
| Trailing price return (1y) | +79.9% |
|---|
Figures
| Trailing EPS | -0.69 |
|---|---|
| Forward EPS | -4.74 |
| Forward P/E | -6.21 |
Revisions
Stable (-0.2%, 10 dates)
Takeaway Low data confidence (limited analyst coverage) — treat this section as informational only.
Business growth vs share price
Revenue grew 101% over the last 3 years.
Share price — No dated price history is cached for this name, so the price cannot be lined up against the filing dates.
Earnings per share — Not shown: 12 of 12 quarters in this window were at or below zero. A series that crosses zero cannot be rebased to a starting value of 100, and forcing it would invert the line.
These are reported figures against the share price over the same window, nothing more. A business growing faster than its stock is not by itself a reason to buy it, and this is not a forecast or a recommendation.
Valuation: dearer or cheaper than usual
BEAM is priced about where it normally is — compared with its own last 5 years, not with other companies. You pay $52.97 for every $1 of sales it makes in a year. Normally that has been about $46.89, and over the 5 years it has swung between $18.42 and $295,680.08. 46% of days in that time were dearer than today.
shaded = the middle half of the last 5 years dashed = its normal level dot = today
For 100% of the last 5 years there is no profit figure to compare the price with, because the company was losing money or nothing was filed. The range covers the rest.
Banks and insurers do not have sales in the ordinary sense, so the "vs sales" figure means little for this company. The profit one is fine.
Cheaper than usual is not the same as a bargain — the price may have fallen for a reason. Profit figures run to March 2026, the latest filed.
Dividends: what it pays you
BEAM pays no dividend. Any return from owning it has to come from the share price. That is an ordinary choice rather than a fault — a company keeping its profit is reinvesting it, buying back shares, or holding it.
Reported earnings
Revenue Net income Derived Q4
12 quarters to Q1 26. Revenue and net income share one scale, so the gap between them is the margin. The baseline is zero — bars below it are losses.
EPS (GAAP) -1.56 to -0.55, own scale
Same 12 quarters as the chart above, on their own axis — EPS is dollars per share, not dollars, so it cannot share a scale with revenue or net income without disappearing next to them.
| Quarter ending | Revenue | YoY | Net income | EPS (GAAP) | EPS reported | vs consensus | Filed |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | 31.74m | +324.9% | -94.32m | -0.91 | -0.91 | +18.6% | 2026-05-07 |
| 2025-09-30 | 9.70m | -32.0% | -112.73m | -1.10 | -1.10 | -3.7% | 2025-11-04 |
| 2025-06-30 | 8.47m | -28.1% | -102.29m | -1.00 | — | — | 2025-08-05 |
| 2025-03-31 | 7.47m | +0.8% | -109.27m | -1.24 | — | — | 2025-05-06 |
| 2024-09-30 | 14.27m | -17.0% | -96.67m | -1.17 | — | — | 2024-11-05 |
| 2024-06-30 | 11.77m | -41.5% | -91.05m | -1.11 | — | — | 2024-08-06 |
| 2024-03-31 | 7.41m | -69.4% | -98.67m | -1.21 | — | — | 2024-05-07 |
| 2023-09-30 | 17.19m | +8.8% | -96.09m | -1.22 | — | — | 2023-11-08 |
| 2023-06-30 | 20.12m | — | -82.78m | -1.08 | — | — | 2023-08-08 |
| 2023-03-31 | 24.21m | — | -96.46m | -1.33 | — | — | 2023-05-10 |
| 2022-12-31 (derived) | 20.04m | — | -38.35m | -0.55 | — | — | 2023-02-28 |
| 2022-09-30 | 15.80m | — | -109.58m | -1.56 | — | — | 2022-11-07 |
How similar companies reacted to their last report
| Peers with a recent report | 4 |
|---|---|
| Direction | 2 up, 2 down on their own last report |
| Typical move | ±3.2% |
Revenue up year on year Revenue down Price rose around the report Price fell around the report separate scales — a crossing means nothing
| Ticker | Quarter ending | Reported | Move around report | Next 20 sessions vs SPY |
|---|---|---|---|---|
| TECH Bio-Techne Corporation | 2026-03-31 | 2026-05-06 (filing date) | -10.2% | +1.5% |
| VRTX Vertex Pharmaceuticals Incorporated | 2026-03-31 | 2026-05-05 (filing date) | -0.5% | +0.1% |
| MRNA Moderna, Inc. | 2026-03-31 | 2026-05-01 (filing date) | +3.0% | -9.3% |
| INCY Incyte Corporation | 2026-03-31 | 2026-04-28 (filing date) | +3.5% | -7.7% |
Peers are same-sector names closest to BEAM by revenue — a coarse comp set, not a hand-picked one.
Share count
Diluted shares Return since the previous filing
| Direction | Growing — shares issued |
|---|---|
| Diluted shares | 103.3M as at 2026-03-31 |
| Change over 1 year | +17.4% |
| Change over 3 years | +42.9% |
| Public float | $1.70bn as at 2025-06-30 (10-K) |
History before 2020-06-30 is not shown. The share count jumps at that date by a ratio no ordinary issuance produces — a split whose factor is not in Brown Bear's split store — so earlier figures are on a different basis and cannot be compared with today's.
Debt levels
| Total debt | $100.3M |
|---|---|
| Cash & equivalents | $219.8M |
| Net debt | −$119.6M |
| Debt / equity | 0.09x |
From the balance sheet in the company's most recent SEC filing (as of 2026-06-30) — not scored or gauged. "Healthy" debt varies hugely by industry: a utility or a REIT normally carries far more leverage than a software company as a matter of course, so this is context to weigh against the rest of the page, not a pass/fail reading. Net debt is negative here — the company holds more cash than debt.
The Pricewhat the chart is doingTop ↑
Price Levels
| Strategy | Fair Value Anchor |
|---|---|
| Reference band | 27.95 — 29.58 |
| Protective stop | 25.27 (Atr, 12.1% risk) |
| Support | 28.49 (3 touches, 3.3% away) |
| Resistance | 31.51 (7.1% away) |
Takeaway The shares are nearer the floor than the ceiling: about 3.3% above 28.49, a price buyers have stepped in at before, and 7.1% below 31.51, where sellers have turned up before. That floor has held 3 times, which is how it was spotted. If someone bought at today's price and sold if it dropped through the level below, they would be about 12.1% out of pocket. That is all this figure means — an illustration of the risk, not a price to sell at.
Levels are computed from price structure. They describe where the engine locates support and extension — they are not targets, and not advice.
Ichimoku Cloud (Adaptive)
| Daily cloud | Price INSIDE the cloud | periods 8/24/47 (91% of classic 9/26/52) |
|---|---|
| Lines | Tenkan/Kijun BEAR | cloud twist BEAR |
| Cloud thickness | 78% percentile |
| Chikou span | Above price from 26 periods ago |
| Weekly cloud | Price ABOVE the weekly cloud (context only, not scored) |
Takeaway The stock is trading inside its cloud — a shaded band drawn from several of its own moving averages, currently 28.20 to 31.46. Inside the band those averages disagree with each other, so the indicator is not saying much either way. Its shorter-term averages agree with that. The band is unusually wide at the moment, so it marks a broad zone rather than a single level.
Trailing returns
| 21 days | +15.3% |
|---|---|
| 63 days | -5.5% |
| 126 days | +2.6% |
| 252 days | +74.7% |
| Below 252d high | 22.4% |
Trend context
| Position | At trend |
|---|---|
| Extension | Normal |
| Trend slope | Rising |
| Direction of travel | Holding its deviation |
Takeaway Price is near a rising Kalman fair trend, consistent with a healthy trend setup.
Volatility
| State | Expanded out of a squeeze |
|---|---|
| Current band width | 20.5% of price |
| Recent tightest | 12.2% (9 sessions ago, narrower than 99.0% of its history) |
| Expansion since | 1.68× |
| Band | 25.31 — 31.08 |
Takeaway Lately this share price has been swinging around inside a range roughly 20% wide, and it recently went unusually quiet — calmer than it has been 99% of the time. It has started moving again since, swinging about 1.7 times as widely as during that quiet spell. A stock that has been quiet tends to make its next move look big by comparison, simply because the recent bar was low.
Historical trends
History begins when the site started recording, not when the company listed, so a short line means a short record and nothing more.
Who's Tradingthe flow behind the priceTop ↑
Insider activity
| Activity | Insider selling |
|---|---|
| Buy filings | 0 |
| Sell filings | 8 |
| Shares sold | 351,900 |
| Value sold | $12.2m |
| Latest sell | 2026-07-27 |
| Filed | Insider | Shares | Value |
|---|---|---|---|
| 2026-07-27 | Sold Simon AmyChief Medical Officer | 16,667 | $429,037 |
| 2026-06-30 | Sold Simon AmyChief Medical Officer | 373 | $12,954 |
| 2026-06-30 | Sold Evans John M.CEO | 23,100 | $791,482 |
| 2026-06-30 | Sold Evans John M.CEO | 1,900 | $66,203 |
| 2026-06-29 | Sold Evans John M.CEO | 13,421 | $471,528 |
| 2026-06-29 | Sold Evans John M.CEO | 11,579 | $415,824 |
Open-market Form 4 purchases and sales over the last 75 days, read from SEC EDGAR Form 4. Grants, option exercises, gifts and shares withheld for tax are excluded — they are compensation mechanics, not a decision to buy or sell. Reported Form 4 activity. Brown Bear tested insider cluster-buying as a return signal and rejected it as era-unstable; shown as fact, not signal.
Insider timeline
| Insider | Filings | Shares | Value |
|---|---|---|---|
| Sold FMR LLC 2026-06-25 – 2026-06-26 (2 days) | 2 | 284,860 | $10.0m |
| Sold Evans John M.CEO 2026-06-29 – 2026-06-30 (2 days) | 4 | 50,000 | $1.7m |
| Sold Simon AmyChief Medical Officer 2026-06-30 – 2026-07-27 (2 days) | 2 | 17,040 | $442.0k |
Open-market purchases and sales only, grouped by person over the last 75 days — one decision is often split across several filings, so the number of filings is not the number of buyers. Sold $12.2m across 3 people. Grants, option exercises, gifts and shares withheld for tax are excluded. Brown Bear has not found insider buying to predict returns on its own, so this is a record of what was filed, not a recommendation.
Volume confirmation
| Volume-price trend | Above its signal line |
|---|---|
| Confirmation | Marginal |
No absorption or distribution event in the recent window.
Takeaway Slightly more shares change hands on rising days than on falling ones, but the gap is too small to read anything into.
Options Positioning
No binary-event flag
BEAM: no binary-event flag. Near IV 103%, far IV 69% (ratio 1.48), implied move 18.2%.
| Implied volatility | 103% near (18d) · 69% far (81d) — Term structure inverted — the market is pricing an event in the near window |
|---|---|
| Term structure | 1.48× near/far |
| Historical volatility | 69% |
| Implied vs historical | 1.48× |
| Implied move | ±18.2% by 2026-09-18 |
| Implied move vs ATR | 0.90× |
| Skew | Call Skew (0.68×) |
| Call wall | 30.00 (+1.9% away) |
| Put wall | 22.00 (-25.2% away) |
| Gamma pin | 30.00 |
- Term structure inverted (near 103% IV vs far 69% IV, ratio 1.48)
Takeaway Insuring against a move in this stock costs more for the next few weeks than for the next few months. Traders usually pay up like that when they know something is coming soon — results, a court ruling, a regulatory decision. Options traders are positioned for a move of around 18.2% in either direction by 2026-09-18.
Chain as at 2026-08-31. This is a risk read on whether a specific event is being priced — not a directional view.
Context & Methodthe record, and how it was builtTop ↑
Relative Rotation
Mixed Rotation Phase
Rotation health 70.5/100; Positive Rotation.
| Rotation health | 70.5 |
|---|---|
| Rotation strength | 79.5 |
| Leg | Quadrant | RS-Ratio | RS-Mom |
|---|---|---|---|
| Stock vs sector | Weakening | 117.5 | 78.7 |
| Stock vs SPY | Weakening | 117.7 | 90.5 |
| Sector vs SPY | Leading | 103.2 | 104.6 |
Direction of travel: South-East / trend strong but momentum cooling
Position only. Brown Bear's RRG redesign programme is closed — five constructions, none beat an appropriate null — so this section describes where the name sits, and is not a signal.
News Headlines
- Loading headlines\u2026
Headlines are supplied by third-party feeds and are not written, ranked or interpreted by Brown Bear. They feed no score on this page.
Detailed Scoring
Positive signals
- Altman Z-score 11.27 (+6.0)
- Insider conviction score (+3.0)
- ROIC improving by 17.4 pts (+3.0)
- FCF margin improving by 299.7 pts (+2.0)
- Track 2: MACD histogram state (0.36) (+5.0)
- Track 2: MACD line/signal trend quality (+15.0)
- Track 2: positive MACD trend regime (+10.0)
- Track 2: MACD slope expanding (+5.0)
- Track 2: relative strength trend improving (+10.0)
- Track 2: 20-day momentum acceleration 0.40 (+20.0)
- Track 2: bullish DI spread 10.7 (+8.0)
- Track 2: ADX 25.3 and rising (+10.0)
- Track 2: relative momentum rank 0.93 (+14.3)
- Track 2: price above EMA20 by 2.6% (+2.1)
- Track 2: EMA20 slope expanding 3.1% (+8.0)
- Track 2: RSI trend quality 60.3, 5-day change +10.4 (+8.3)
- Track 2: VPT strength 0.03 (+0.6)
- Track 2: price above EMA50 by 1.6% (+1.3)
- Track 2: EMA50 slope improving 0.7% (+1.6)
- Track 2: Bollinger position 0.71 (+5.7)
Negative signals
- Track 2: weak volume for momentum setup (0.78x average)
- Weak Piotroski F-score (2/9)
- Gross margin improving by -261.9 pts (+-1.0)
- Poor earnings quality (accrual ratio 0.179)
- Track 2 structural exemption: structural score 0.0/100 below the 25 quality floor; this is an unowned speculative candidate, so the universal SELL gate was skipped and the Track 2 momentum/RRG grid was allowed to evaluate instead. Structural quality here is weak by design for this kind of candidate -- treat any resulting BUY as higher risk than a Track 1 signal.
Chase risk is not elevated for this name, so extension penalties are omitted from the negative signals above.